$VXIT Virexit Technologies, Inc. Secures Direct U
Post# of 52
(Total Views: 38)
Posted On: 05/15/2025 11:16:54 AM
$VXIT Virexit Technologies, Inc. Secures Direct U.S. Rights to Distribute Airros(TM) Sanitation System
https://www.accessnewswire.com/newsroom/en/bu...bu-1002120
VirExit Technologies, Inc. Secures Direct U.S. Rights to Distribute AirROS™ Sanitation System
High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows – Poised to Drive 35% Operational Profit
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 – VirExit Technologies, Inc. (OTC PINK: VXIT) ("VirExit" or the "Company"
, a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE" . This agreement establishes VirExit as the U.S. distributor of AirROS’s patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027.
Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 – 30.5% of total AirROS sales – scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.
Disruptive Technology Meets Rapid Market Expansion
AirROS’s proprietary ROS technology continuously neutralizes viruses, bacteria, molds, and odors—without chemical residues—earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening indoor air quality (IAQ) mandates in schools, healthcare, and hospitality, VirExit’s nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.
Consumer Market Expansion & Public Health Impact
To complement its B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).
Mold & Indoor Allergens
Current State: Roughly 50% of U.S. homes contend with visible mold or dampness; up to 20% of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).
AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99%, reducing allergy flare-ups and related healthcare costs.
Childhood Asthma & Seasonal Pathogens
Current State: Asthma affects 1 in 13 Americans (~25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.
AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40%, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.
Elderly & Immunocompromised Households
Current State: As immune defenses wane with age, older adults (12% of the U.S. population) face higher rates of respiratory infections and hospital admissions—burdening families and the healthcare system.
AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.
By bridging enterprise and consumer offerings, VirExit not only multiplies its addressable market—but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.
Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals:
Office Buildings ($1.2B market): Delivering 10–20% HVAC savings and 35% fewer sick-days
Schools & Universities ($0.7B market): Driving a 30% drop in absenteeism
Long-Term Care ($1.0B market): Achieving 40% fewer hospital-acquired infections
After validating these results, VirExit will extend into 15 major metro areas, rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2–7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS’s upfront investment—recouped through energy savings, reduced maintenance, and fewer sick-day losses—pays for itself in under 18 months. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.VirExit Technologies, Inc. Secures Direct U.S. Rights to Distribute AirROS™ Sanitation System
High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows – Poised to Drive 35% Operational Profit
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 – VirExit Technologies, Inc. (OTC PINK: VXIT) ("VirExit" or the "Company" , a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE" . This agreement establishes VirExit as the U.S. distributor of AirROS’s patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027.
Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 – 30.5% of total AirROS sales – scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.
Disruptive Technology Meets Rapid Market Expansion
AirROS’s proprietary ROS technology continuously neutralizes viruses, bacteria, molds, and odors—without chemical residues—earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening indoor air quality (IAQ) mandates in schools, healthcare, and hospitality, VirExit’s nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.
“By combining SAGE’s breakthrough ROS platform with VirExit’s proven go-to-market engine, we’re not only enhancing safety but unlocking a durable, subscription-driven growth engine,” said James Katzaroff, CEO of VirExit Technologies. “Investors should expect steady quarterly revenue inflections, robust margin expansion, and a clear pathway to positive cash flow by mid-2026.”
“VirExit’s market reach and ESG-aligned vision make them the ideal partner to scale AirROS,” added Brian Taylor, CEO of SAGE Industrial. “Together, we’ll set a new industry benchmark in continuous, on-site sanitation.”
Consumer Market Expansion & Public Health Impact
To complement its B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).
Mold & Indoor Allergens
Current State: Roughly 50% of U.S. homes contend with visible mold or dampness; up to 20% of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).
AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99%, reducing allergy flare-ups and related healthcare costs.
Childhood Asthma & Seasonal Pathogens
Current State: Asthma affects 1 in 13 Americans (~25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.
AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40%, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.
Elderly & Immunocompromised Households
Current State: As immune defenses wane with age, older adults (12% of the U.S. population) face higher rates of respiratory infections and hospital admissions—burdening families and the healthcare system.
AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.
By bridging enterprise and consumer offerings, VirExit not only multiplies its addressable market—but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.
Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals:
Office Buildings ($1.2B market): Delivering 10–20% HVAC savings and 35% fewer sick-days
Schools & Universities ($0.7B market): Driving a 30% drop in absenteeism
Long-Term Care ($1.0B market): Achieving 40% fewer hospital-acquired infections
After validating these results, VirExit will extend into 15 major metro areas, rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2–7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS’s upfront investment—recouped through energy savings, reduced maintenance, and fewer sick-day losses—pays for itself in under 18 months. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.
https://www.accessnewswire.com/newsroom/en/bu...bu-1002120
VirExit Technologies, Inc. Secures Direct U.S. Rights to Distribute AirROS™ Sanitation System
High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows – Poised to Drive 35% Operational Profit
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 – VirExit Technologies, Inc. (OTC PINK: VXIT) ("VirExit" or the "Company"
, a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE" . This agreement establishes VirExit as the U.S. distributor of AirROS’s patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027. Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 – 30.5% of total AirROS sales – scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.
Disruptive Technology Meets Rapid Market Expansion
AirROS’s proprietary ROS technology continuously neutralizes viruses, bacteria, molds, and odors—without chemical residues—earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening indoor air quality (IAQ) mandates in schools, healthcare, and hospitality, VirExit’s nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.
Consumer Market Expansion & Public Health Impact
To complement its B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).
Mold & Indoor Allergens
Current State: Roughly 50% of U.S. homes contend with visible mold or dampness; up to 20% of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).
AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99%, reducing allergy flare-ups and related healthcare costs.
Childhood Asthma & Seasonal Pathogens
Current State: Asthma affects 1 in 13 Americans (~25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.
AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40%, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.
Elderly & Immunocompromised Households
Current State: As immune defenses wane with age, older adults (12% of the U.S. population) face higher rates of respiratory infections and hospital admissions—burdening families and the healthcare system.
AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.
By bridging enterprise and consumer offerings, VirExit not only multiplies its addressable market—but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.
Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals:
Office Buildings ($1.2B market): Delivering 10–20% HVAC savings and 35% fewer sick-days
Schools & Universities ($0.7B market): Driving a 30% drop in absenteeism
Long-Term Care ($1.0B market): Achieving 40% fewer hospital-acquired infections
After validating these results, VirExit will extend into 15 major metro areas, rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2–7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS’s upfront investment—recouped through energy savings, reduced maintenance, and fewer sick-day losses—pays for itself in under 18 months. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.VirExit Technologies, Inc. Secures Direct U.S. Rights to Distribute AirROS™ Sanitation System
High-Margin Hardware Plus Recurring Service Contracts Deliver Predictable Cash Flows – Poised to Drive 35% Operational Profit
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 15, 2025 – VirExit Technologies, Inc. (OTC PINK: VXIT) ("VirExit" or the "Company"
, a pioneer in health-safety innovation, today announced a direct national reseller agreement with AirROS™ by SAGE Industrial Corporation ("SAGE" . This agreement establishes VirExit as the U.S. distributor of AirROS’s patented Reactive Oxygen Species (ROS) air-and-surface sanitation systems across the United States, positioning the Company to generate $196,721 in AirROS revenue in the second half of fiscal 2025, scaling to $786,885 in fiscal 2026 and $1,572,770 in fiscal 2027. Investor Impact & ROI Acceleration
Under this partnership, VirExit will realize high-margin hardware sales coupled with a subscription-based model for filter replacements, remote monitoring, and preventive maintenance. Management now projects that by 2H FY 2025, recurring service revenues will total $60,000 – 30.5% of total AirROS sales – scaling to $240,000 (30.5%) in FY 2026 and $480,000 (30.5%) in FY 2027. This model sustains a blended gross margin of 53% and delivers a projected payback period of under 18 months per installation.
Disruptive Technology Meets Rapid Market Expansion
AirROS’s proprietary ROS technology continuously neutralizes viruses, bacteria, molds, and odors—without chemical residues—earning independent lab validation for up to 99.99% pathogen reduction within 30 minutes. With regulatory bodies tightening indoor air quality (IAQ) mandates in schools, healthcare, and hospitality, VirExit’s nationwide launch is timed to leverage a 6.7% CAGR market projected to exceed $8 billion by 2028.
“By combining SAGE’s breakthrough ROS platform with VirExit’s proven go-to-market engine, we’re not only enhancing safety but unlocking a durable, subscription-driven growth engine,” said James Katzaroff, CEO of VirExit Technologies. “Investors should expect steady quarterly revenue inflections, robust margin expansion, and a clear pathway to positive cash flow by mid-2026.”
“VirExit’s market reach and ESG-aligned vision make them the ideal partner to scale AirROS,” added Brian Taylor, CEO of SAGE Industrial. “Together, we’ll set a new industry benchmark in continuous, on-site sanitation.”
Consumer Market Expansion & Public Health Impact
To complement its B2B footprint, VirExit will introduce the AirROS™ Home unit for residential consumers in Q4 2025. This launch opens access to an estimated 128 million U.S. households (and over 2 billion homes globally) in the $2.1 billion U.S. residential air-purifier market (projected $7.2 billion worldwide).
Mold & Indoor Allergens
Current State: Roughly 50% of U.S. homes contend with visible mold or dampness; up to 20% of Americans report mold-related symptoms (nasal congestion, headaches, fatigue).
AirROS Home Benefit: Lab-validated to slash airborne mold spores by >99%, reducing allergy flare-ups and related healthcare costs.
Childhood Asthma & Seasonal Pathogens
Current State: Asthma affects 1 in 13 Americans (~25 million people), including 6 million children, leading to 5.5 million lost school days annually. The "back-to-school" season sees spikes in viral and bacterial transmission at home.
AirROS Home Benefit: Continuous ROS sanitation can cut asthma attack frequency by up to 40%, curb household pathogen loads in high-risk months, and help families avoid costly ER visits and missed workdays.
Elderly & Immunocompromised Households
Current State: As immune defenses wane with age, older adults (12% of the U.S. population) face higher rates of respiratory infections and hospital admissions—burdening families and the healthcare system.
AirROS Home Benefit: Provides round-the-clock air-and-surface safety, lowering infection risk for vulnerable residents and reducing dependence on expensive facility upgrades or professional cleanings.
By bridging enterprise and consumer offerings, VirExit not only multiplies its addressable market—but also creates a direct, recurring-revenue channel through replacement cartridges and service plans. Investors should anticipate sustainable revenue contributions from both B2B installations and the rapidly growing residential segment beginning in Q4 2025.
Strategic B2B Roll-Out & High-Value Verticals
VirExit is launching targeted pilot programs in three cornerstone verticals:
Office Buildings ($1.2B market): Delivering 10–20% HVAC savings and 35% fewer sick-days
Schools & Universities ($0.7B market): Driving a 30% drop in absenteeism
Long-Term Care ($1.0B market): Achieving 40% fewer hospital-acquired infections
After validating these results, VirExit will extend into 15 major metro areas, rolling out across retail, commercial & government, and hospitality sectors. A tiered referral incentive program (offering partners 2–7% of profits) will fuel rapid channel adoption, while bespoke ROI calculators make it crystal clear that AirROS’s upfront investment—recouped through energy savings, reduced maintenance, and fewer sick-day losses—pays for itself in under 18 months. Real-time monitoring dashboards then empower facility managers to continuously track both cost savings and occupant wellbeing improvements at every site.
(0)
(0)